Washington – October 16, 2026 -- Nearly half of patients with hormone receptor positive, HER2 negative advanced breast cancer develop resistance to first-line endocrine therapy driven by the ESR1 mutation (ESR1m), according to a new Academy of Managed Care Pharmacy (AMCP) Market Insights Program report. The report finds that biomarker testing and treatment paradigms are evolving faster than the evidence payers need to manage them.

Sydney – October 12, 2026 -- The Safety Review Committee (SRC) for Racura Oncology's HARNESS-1 trial has cleared lead drug RC220 to escalate to 100 mg/m2, after finding no dose-limiting toxicities in either Cohort 1 patient. The Phase 1a/b study combines RC220 with osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Holon, Israel – October 6, 2026 -- Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN) will join a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference, a virtual event running October 8-9, 2026.

Management confirms October 8 session with live investor webcast

The fireside chat is scheduled for Thursday, October 8, 2026, at 9:30 AM ET. A live webcast will stream via the Investor Relations events page on Compugen's website, with a replay available afterward.

North Bethesda, Md. – September 24, 2026 -- The International Society for Pharmaceutical Engineering (ISPE) will convene its 2026 Annual Meeting & Expo in Washington, D.C. from October 18-21, drawing pharmaceutical manufacturing leaders for four days of hybrid sessions combining in-person and virtual attendance.

Pune, India – September 22, 2026 -- The global lupus nephritis market was valued at $1.96 billion in 2025 and is projected to reach $4.08 billion by 2034, expanding at a compound annual growth rate of 8.5% through the forecast period, according to a new analysis by Maximize Market Research.

Holon, Israel – September 22, 2026 -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) will host a virtual key opinion leader event on October 5, 2026 at 8:00 AM ET, presenting new detail on COM701, its anti-PVRIG antibody candidate for relapsed platinum-sensitive ovarian cancer (PSOC).

Shanghai – September 09, 2026 -- Harbour BioMed (HKEX: 02142.HK) shares became eligible for trading under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening direct access for qualified mainland Chinese investors effective immediately.

Market capitalization crosses HK$10 billion threshold

The inclusion follows the Company's market capitalization steadily surpassing HK$10 billion, placing it among large- and mid-cap biopharmaceutical issuers on the Hong Kong exchange.